Paravertebral block and persistent postoperative pain after breast surgery: meta-analysis and trial sequential analysis

Anaesthesia ◽  
2016 ◽  
Vol 71 (12) ◽  
pp. 1471-1481 ◽  
Author(s):  
M. Heesen ◽  
M. Klimek ◽  
R. Rossaint ◽  
G. Imberger ◽  
S. Straube
2015 ◽  
Vol 5;18 (5;9) ◽  
pp. E757-E780 ◽  
Author(s):  
Abdullah S. Terkawi

Background: While most trials of thoracic paravertebral nerve blocks (TPVB) for breast surgery show benefit, their effect on postoperative pain intensity, opioid consumption, and prevention of chronic postsurgical pain varies substantially across studies. Variability may result from use of different drugs and techniques. Objectives: To examine the use of TPVB in breast surgery, and to determine which method(s) provide optimal efficacy and safety. Study Design: Mixed-Effects Meta-Analysis. Methods: We conducted a systematic review of randomized trials comparing TPVB to no intervention using random-effects models. To evaluate the contributions of various techniques, clinical approaches were included as moderators in mixed-effects models. Results: A total of 24 randomized controlled trials (RCTs) with 1,822 patients were included. Use of TPVB decreased postoperative pain scores at rest and movement at the first 2, 24, 48, and 72 hours. TPVB modestly decreased intraoperative and postoperative opioid consumption, reduced nausea and vomiting, and shortened hospitalization, but to a probably clinically irrelevant degree. Blocks also appeared to reduce the incidence of chronic postsurgical pain at 6 months. Adding fentanyl to the TPVB improved pain at rest (at 24, 48, and 72 hours) and movement (at 24 and 72 hours). Multilevel blocks provided better postoperative pain control, but only during movement (at 2, 48, and 72 hours). Fewer procedural complications (especially hypotension, epidural spread, and Horner’s syndrome) occurred when anatomical landmarks were supplemented with ultrasound guidance. Limitations: The number of studies available was limited in the meta-analytic model of incidence of chronic post-surgical pain. Conclusion: TPVB reduces postoperative pain and opioid consumption, and has a limited beneficial effect on the quality of recovery. From all the techniques that were evaluated, only the addition of fentanyl, and performing multilevel blocks were associated with improved acute analgesia. TPVB may reduce chronic postsurgical pain at 6 months. Key words: Thoracic paravertebral block, breast surgery, anesthesia, acute pain, chronic pain, nausea, vomiting, length of stay, techniques, variability, meta-regression, meta-analysis, moderators


2017 ◽  
Vol 7 (20;7) ◽  
pp. 569-595
Author(s):  
Fu-hai Ji

Background: It is still a challenge to optimize postoperative pain management. The effects of adding dexmedetomidine (DEX) to opioid-based postoperative intravenous patient-controlled analgesia (PCA) are not fully understood. Objectives: The aim of this study is to assess the efficacy and safety of opioid-DEX combinations for postoperative PCA, and a trial sequential analysis (TSA) is utilized to evaluate the robustness of the current evidence. Study Design: A systematic review and meta-analysis. Setting: Randomized controlled trials that compared opioid-DEX combinations with opioid-only for PCA in adult surgical patients. Methods: MEDLINE, EMBASE, and CENTRAL databases were searched for relevant articles. The main outcomes analyzed were postoperative pain intensity, opioid requirement, and opioid-related adverse events. The random-effects model was used to estimate mean differences (MDs) or relative risks (RRs) with 95% confidence intervals (CIs). A TSA was performed to test whether the evidence was reliable and significant. The quality of evidence for the main outcomes was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. Results: Eighteen studies involving 1,284 patients were included. The meta-analysis indicated that opioid-DEX combinations were associated with lower postoperative pain intensity (at rest: MD [24 hours] = -0.48, 95% CI [-0.75, -0.21], P = 0.0005), lower morphine-equivalent requirement (MD [0 – 24 hours] = -12.16 mg [-16.12, -8.21], P < 0.00001), and lower adverse events (nausea: RR = 0.66 [0.52, 0.83]; vomiting: RR = 0.65 [0.49, 0.87]; and pruritus: RR = 0.57 [0.40, 0.81]). For the above results, the TSA revealed that the cumulative Z-curve exceeded both the traditional boundary and the trial sequential monitoring boundary for benefit. DEX had no effect on the incidence of hypotension or bradycardia, which was also confirmed by the TSA. The GRADE level of evidence was high for postoperative nausea, moderate for pain intensity at rest at 24 hours postoperatively, morphine-equivalent requirement during 0 – 24 hours postoperatively, and postoperative vomiting, pruritus, and bradycardia, and low for postoperative hypotension. Limitations: The risk of introducing potentially significant heterogeneity exists, and this study did not evaluate the effects of DEX combined with opioids on long-term outcomes including chronic pain and patients’ satisfaction after hospital discharge. Conclusions: Postoperative PCA strategies with opioid-DEX combinations decreased postoperative pain, opioid requirement, and opioid-related adverse events. DEX is a useful adjuvant to opioid-based PCA. Key words: Dexmedetomidine, pain, postoperative analgesia, opioid, patient-controlled


Sign in / Sign up

Export Citation Format

Share Document